Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Beta Bionics
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Beta Bionics posts Q2 beats on 38% sales growth
Beta Bionics (Nasdaq:BBNX) today reported second-quarter financial results that topped the consensus estimates on Wall Street. Shares of BBNX remained unmoved at $15.17 apiece after the market closed today. The Irvine, California-based automated insulin delivery technology developer reported losses of $23.4 million in the quarter. That equals 53¢ per share on sales of $32 million […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Beta Bionics real-world data shows 25% time in range improvement with iLet
Beta Bionics (Nasdaq:BBNX) said real-world data discussed last weekend highlighted the impact of its iLet Bionic Pancreas platform. The company said conversations with clinicians at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans covered improved outcomes and easier follow-up visits. The Irvine, California-based company said outcomes demonstrated how iLet supports diabetes care […]
Beta Bionics makes near-real-time, real-world bionic pancreas data publicly available
Beta Bionics (Nasdaq:BBNX) today announced the public availability of near-real-time, real-world iLet Bionic Pancreas data. Irvine, California-based Beta Bionics said its dashboard publishes outcomes for 100% of iLet patients who meet two simple, pre-stated criteria (a provider-reported baseline HbA1c and at least two weeks of data uploaded to the cloud), with no exclusions applied. According […]
Beta Bionics earmarks Q2 2027 for Mint patch pump launch, shares details on new tech
Beta Bionics (Nasdaq:BBNX) today provided an update on its expected commercialization timeline for its Mint patch pump system. Irvine, California-based Beta Bionics said it expects to fully commercialize Mint by the end of the second quarter of 2027. This represents an accelerated timeline compared to previous expectations for the end of 2027. The automated insulin […]
Beta Bionics increases 2026 sales guidance on 57% Q1 growth
Beta Bionics (Nasdaq:BBNX) today reported first-quarter sales results that came in ahead of the forecast on Wall Street. For the full year, the company expects sales to range between $131 million and $136 million. It previously forecast between $130 million and $135 million. Shares of Beta Bionics fell 2% to $12.03 apiece after the market […]
Beta Bionics introduces new insights feature with automated insulin delivery tech
Beta Bionics (Nasdaq:BBNX) announced today that it launched Bionic Insights, a new feature for healthcare providers and people with diabetes. The new feature further bolsters the company’s iLet automated insulin delivery system platform. Meanwhile, the company looks poised to add further offerings with the planned “Mint” patch pump, eyeing on a 2027 launch. Irvine, California-based […]
Beta Bionics sales grow 57% in Street-beating Q4, guidance set for 2026
Beta Bionics (Nasdaq:BBNX) shares rose slightly after hours today on fourth-quarter results that topped the consensus forecast. Shares of BBNX ticked up about 1% to $14.10 apiece in post-market trading today. The Irvine, California-based automated insulin delivery system developer reported losses of $13.5 million. That equals 38¢ per share on sales of $32.1 million for […]
